Fibrocell Science announces positive results from iPS cells study
Aug 30, 2013 (MarketLine via COMTEX) --
Fibrocell Science, Inc., a biotechnology company, has announced positive results from a study demonstrating a potential mechanism for converting research-grade adult skin cells into clinical grade induced pluripotent stem, or iPS, cells.
In addition to providing proof of concept for this reprogramming method of converting adult skin cells to iPS cells, the study confirmed that researchers can effectively remove unwanted non-human contaminants from stem cell populations derived under research-grade conditions. A variety of tests were used to determine whether the converted stem cell population was viable, expressed markers identifying them as stem cells, was free of microorganisms and no longer expressed non-human contaminants. Positive test results proved that these stem cells were free of unwanted non-human factors, the company said.
The iPS cells generated from the study were also well-characterized, including confirmation of the ability to transform into other critical cell types such as those of the brain, liver and heart. The cells were converted to clinical grade in a UCLA facility that meets the requirements of current good manufacturing practices (cGMP) for producing personalized cellular therapies. The cellular characterization research, factor-free confirmation assays and cGMP manufacturing process are essential to the conversion of research-grade biologics into clinical-grade biologics, the company added.
"We are excited about our collaboration with UCLA and this important step forward as we continue to build our intellectual property portfolio around skin-derived iPS and neural stem cells both of which hold potential for future discovery and development of autologous cellular therapeutics," said David Pernock, Chairman and CEO of Fibrocell Science.
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
[ Back To Technology News's Homepage ]